The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global AAV-based Gene Therapy Products Market Research Report 2025
Synopsis
AAV-based gene therapy products utilize adeno-associated virus (AAV) vectors as delivery vehicles to transfer therapeutic genes into target cells for the treatment of various genetic disorders and diseases. AAV vectors are non-pathogenic viruses that can efficiently infect a wide range of cells and have a low immunogenicity profile, making them suitable candidates for gene therapy applications. In AAV-based gene therapy, the therapeutic gene of interest is inserted into the AAV vector's genome, and the vector is then administered to the patient, typically via intravenous injection or direct injection into the affected tissue. Once inside the target cells, the AAV vector delivers the therapeutic gene, allowing it to be expressed and produce the desired therapeutic protein. AAV-based gene therapy products hold significant promise for the treatment of inherited genetic disorders, as well as acquired diseases such as certain types of cancer and neurodegenerative disorders, offering potential long-term therapeutic benefits with a single administration.
The global AAV-based Gene Therapy Products market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for AAV-based Gene Therapy Products is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for AAV-based Gene Therapy Products is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of AAV-based Gene Therapy Products include uniQure, Spark Therapeutics, AveXis (Novartis), PTC Therapeutics, BioMarin, Sarepta Therapeutics, Roche, Pfizer, CSL Behring, Sangamo Therapeutics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for AAV-based Gene Therapy Products, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding AAV-based Gene Therapy Products.
The AAV-based Gene Therapy Products market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global AAV-based Gene Therapy Products market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the AAV-based Gene Therapy Products manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
uniQure
Spark Therapeutics
AveXis (Novartis)
PTC Therapeutics
BioMarin
Sarepta Therapeutics
Roche
Pfizer
CSL Behring
Sangamo Therapeutics
Biogen
Freeline Therapeutics
Coave Therapeutics
MeiraGTx
RegenxBio
Asklepios Biopharmaceutical
Audentes Therapeutics
Neurophth
Belief BioMed
Segment by Type
AAV2
AAV8
AAV9
Others
Segment by Application
Haematology
Ophthalmology
Neurology
Musculoskeletal
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of AAV-based Gene Therapy Products manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of AAV-based Gene Therapy Products in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
AAV-based gene therapy products utilize adeno-associated virus (AAV) vectors as delivery vehicles to transfer therapeutic genes into target cells for the treatment of various genetic disorders and diseases. AAV vectors are non-pathogenic viruses that can efficiently infect a wide range of cells and have a low immunogenicity profile, making them suitable candidates for gene therapy applications. In AAV-based gene therapy, the therapeutic gene of interest is inserted into the AAV vector's genome, and the vector is then administered to the patient, typically via intravenous injection or direct injection into the affected tissue. Once inside the target cells, the AAV vector delivers the therapeutic gene, allowing it to be expressed and produce the desired therapeutic protein. AAV-based gene therapy products hold significant promise for the treatment of inherited genetic disorders, as well as acquired diseases such as certain types of cancer and neurodegenerative disorders, offering potential long-term therapeutic benefits with a single administration.
The global AAV-based Gene Therapy Products market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for AAV-based Gene Therapy Products is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for AAV-based Gene Therapy Products is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of AAV-based Gene Therapy Products include uniQure, Spark Therapeutics, AveXis (Novartis), PTC Therapeutics, BioMarin, Sarepta Therapeutics, Roche, Pfizer, CSL Behring, Sangamo Therapeutics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for AAV-based Gene Therapy Products, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding AAV-based Gene Therapy Products.
The AAV-based Gene Therapy Products market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global AAV-based Gene Therapy Products market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the AAV-based Gene Therapy Products manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
uniQure
Spark Therapeutics
AveXis (Novartis)
PTC Therapeutics
BioMarin
Sarepta Therapeutics
Roche
Pfizer
CSL Behring
Sangamo Therapeutics
Biogen
Freeline Therapeutics
Coave Therapeutics
MeiraGTx
RegenxBio
Asklepios Biopharmaceutical
Audentes Therapeutics
Neurophth
Belief BioMed
Segment by Type
AAV2
AAV8
AAV9
Others
Segment by Application
Haematology
Ophthalmology
Neurology
Musculoskeletal
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of AAV-based Gene Therapy Products manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of AAV-based Gene Therapy Products in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 AAV-based Gene Therapy Products Market Overview
1.1 Product Definition
1.2 AAV-based Gene Therapy Products by Type
1.2.1 Global AAV-based Gene Therapy Products Market Value Comparison by Type (2024-2030)
1.2.2 AAV2
1.2.3 AAV8
1.2.4 AAV9
1.2.5 Others
1.3 AAV-based Gene Therapy Products by Application
1.3.1 Global AAV-based Gene Therapy Products Market Value by Application (2024-2030)
1.3.2 Haematology
1.3.3 Ophthalmology
1.3.4 Neurology
1.3.5 Musculoskeletal
1.3.6 Others
1.4 Global AAV-based Gene Therapy Products Market Size Estimates and Forecasts
1.4.1 Global AAV-based Gene Therapy Products Revenue 2019-2030
1.4.2 Global AAV-based Gene Therapy Products Sales 2019-2030
1.4.3 Global AAV-based Gene Therapy Products Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 AAV-based Gene Therapy Products Market Competition by Manufacturers
2.1 Global AAV-based Gene Therapy Products Sales Market Share by Manufacturers (2019-2024)
2.2 Global AAV-based Gene Therapy Products Revenue Market Share by Manufacturers (2019-2024)
2.3 Global AAV-based Gene Therapy Products Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of AAV-based Gene Therapy Products, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of AAV-based Gene Therapy Products, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of AAV-based Gene Therapy Products, Product Type & Application
2.7 Global Key Manufacturers of AAV-based Gene Therapy Products, Date of Enter into This Industry
2.8 Global AAV-based Gene Therapy Products Market Competitive Situation and Trends
2.8.1 Global AAV-based Gene Therapy Products Market Concentration Rate
2.8.2 The Global 5 and 10 Largest AAV-based Gene Therapy Products Players Market Share by Revenue
2.8.3 Global AAV-based Gene Therapy Products Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global AAV-based Gene Therapy Products Market Scenario by Region
3.1 Global AAV-based Gene Therapy Products Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global AAV-based Gene Therapy Products Sales by Region: 2019-2030
3.2.1 Global AAV-based Gene Therapy Products Sales by Region: 2019-2024
3.2.2 Global AAV-based Gene Therapy Products Sales by Region: 2025-2030
3.3 Global AAV-based Gene Therapy Products Revenue by Region: 2019-2030
3.3.1 Global AAV-based Gene Therapy Products Revenue by Region: 2019-2024
3.3.2 Global AAV-based Gene Therapy Products Revenue by Region: 2025-2030
3.4 North America AAV-based Gene Therapy Products Market Facts & Figures by Country
3.4.1 North America AAV-based Gene Therapy Products Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America AAV-based Gene Therapy Products Sales by Country (2019-2030)
3.4.3 North America AAV-based Gene Therapy Products Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe AAV-based Gene Therapy Products Market Facts & Figures by Country
3.5.1 Europe AAV-based Gene Therapy Products Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe AAV-based Gene Therapy Products Sales by Country (2019-2030)
3.5.3 Europe AAV-based Gene Therapy Products Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific AAV-based Gene Therapy Products Market Facts & Figures by Region
3.6.1 Asia Pacific AAV-based Gene Therapy Products Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific AAV-based Gene Therapy Products Sales by Region (2019-2030)
3.6.3 Asia Pacific AAV-based Gene Therapy Products Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America AAV-based Gene Therapy Products Market Facts & Figures by Country
3.7.1 Latin America AAV-based Gene Therapy Products Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America AAV-based Gene Therapy Products Sales by Country (2019-2030)
3.7.3 Latin America AAV-based Gene Therapy Products Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa AAV-based Gene Therapy Products Market Facts & Figures by Country
3.8.1 Middle East and Africa AAV-based Gene Therapy Products Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa AAV-based Gene Therapy Products Sales by Country (2019-2030)
3.8.3 Middle East and Africa AAV-based Gene Therapy Products Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global AAV-based Gene Therapy Products Sales by Type (2019-2030)
4.1.1 Global AAV-based Gene Therapy Products Sales by Type (2019-2024)
4.1.2 Global AAV-based Gene Therapy Products Sales by Type (2025-2030)
4.1.3 Global AAV-based Gene Therapy Products Sales Market Share by Type (2019-2030)
4.2 Global AAV-based Gene Therapy Products Revenue by Type (2019-2030)
4.2.1 Global AAV-based Gene Therapy Products Revenue by Type (2019-2024)
4.2.2 Global AAV-based Gene Therapy Products Revenue by Type (2025-2030)
4.2.3 Global AAV-based Gene Therapy Products Revenue Market Share by Type (2019-2030)
4.3 Global AAV-based Gene Therapy Products Price by Type (2019-2030)
5 Segment by Application
5.1 Global AAV-based Gene Therapy Products Sales by Application (2019-2030)
5.1.1 Global AAV-based Gene Therapy Products Sales by Application (2019-2024)
5.1.2 Global AAV-based Gene Therapy Products Sales by Application (2025-2030)
5.1.3 Global AAV-based Gene Therapy Products Sales Market Share by Application (2019-2030)
5.2 Global AAV-based Gene Therapy Products Revenue by Application (2019-2030)
5.2.1 Global AAV-based Gene Therapy Products Revenue by Application (2019-2024)
5.2.2 Global AAV-based Gene Therapy Products Revenue by Application (2025-2030)
5.2.3 Global AAV-based Gene Therapy Products Revenue Market Share by Application (2019-2030)
5.3 Global AAV-based Gene Therapy Products Price by Application (2019-2030)
6 Key Companies Profiled
6.1 uniQure
6.1.1 uniQure Company Information
6.1.2 uniQure Description and Business Overview
6.1.3 uniQure AAV-based Gene Therapy Products Sales, Revenue and Gross Margin (2019-2024)
6.1.4 uniQure AAV-based Gene Therapy Products Product Portfolio
6.1.5 uniQure Recent Developments/Updates
6.2 Spark Therapeutics
6.2.1 Spark Therapeutics Company Information
6.2.2 Spark Therapeutics Description and Business Overview
6.2.3 Spark Therapeutics AAV-based Gene Therapy Products Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Spark Therapeutics AAV-based Gene Therapy Products Product Portfolio
6.2.5 Spark Therapeutics Recent Developments/Updates
6.3 AveXis (Novartis)
6.3.1 AveXis (Novartis) Company Information
6.3.2 AveXis (Novartis) Description and Business Overview
6.3.3 AveXis (Novartis) AAV-based Gene Therapy Products Sales, Revenue and Gross Margin (2019-2024)
6.3.4 AveXis (Novartis) AAV-based Gene Therapy Products Product Portfolio
6.3.5 AveXis (Novartis) Recent Developments/Updates
6.4 PTC Therapeutics
6.4.1 PTC Therapeutics Company Information
6.4.2 PTC Therapeutics Description and Business Overview
6.4.3 PTC Therapeutics AAV-based Gene Therapy Products Sales, Revenue and Gross Margin (2019-2024)
6.4.4 PTC Therapeutics AAV-based Gene Therapy Products Product Portfolio
6.4.5 PTC Therapeutics Recent Developments/Updates
6.5 BioMarin
6.5.1 BioMarin Company Information
6.5.2 BioMarin Description and Business Overview
6.5.3 BioMarin AAV-based Gene Therapy Products Sales, Revenue and Gross Margin (2019-2024)
6.5.4 BioMarin AAV-based Gene Therapy Products Product Portfolio
6.5.5 BioMarin Recent Developments/Updates
6.6 Sarepta Therapeutics
6.6.1 Sarepta Therapeutics Company Information
6.6.2 Sarepta Therapeutics Description and Business Overview
6.6.3 Sarepta Therapeutics AAV-based Gene Therapy Products Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Sarepta Therapeutics AAV-based Gene Therapy Products Product Portfolio
6.6.5 Sarepta Therapeutics Recent Developments/Updates
6.7 Roche
6.7.1 Roche Company Information
6.7.2 Roche Description and Business Overview
6.7.3 Roche AAV-based Gene Therapy Products Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Roche AAV-based Gene Therapy Products Product Portfolio
6.7.5 Roche Recent Developments/Updates
6.8 Pfizer
6.8.1 Pfizer Company Information
6.8.2 Pfizer Description and Business Overview
6.8.3 Pfizer AAV-based Gene Therapy Products Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Pfizer AAV-based Gene Therapy Products Product Portfolio
6.8.5 Pfizer Recent Developments/Updates
6.9 CSL Behring
6.9.1 CSL Behring Company Information
6.9.2 CSL Behring Description and Business Overview
6.9.3 CSL Behring AAV-based Gene Therapy Products Sales, Revenue and Gross Margin (2019-2024)
6.9.4 CSL Behring AAV-based Gene Therapy Products Product Portfolio
6.9.5 CSL Behring Recent Developments/Updates
6.10 Sangamo Therapeutics
6.10.1 Sangamo Therapeutics Company Information
6.10.2 Sangamo Therapeutics Description and Business Overview
6.10.3 Sangamo Therapeutics AAV-based Gene Therapy Products Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Sangamo Therapeutics AAV-based Gene Therapy Products Product Portfolio
6.10.5 Sangamo Therapeutics Recent Developments/Updates
6.11 Biogen
6.11.1 Biogen Company Information
6.11.2 Biogen Description and Business Overview
6.11.3 Biogen AAV-based Gene Therapy Products Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Biogen AAV-based Gene Therapy Products Product Portfolio
6.11.5 Biogen Recent Developments/Updates
6.12 Freeline Therapeutics
6.12.1 Freeline Therapeutics Company Information
6.12.2 Freeline Therapeutics Description and Business Overview
6.12.3 Freeline Therapeutics AAV-based Gene Therapy Products Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Freeline Therapeutics AAV-based Gene Therapy Products Product Portfolio
6.12.5 Freeline Therapeutics Recent Developments/Updates
6.13 Coave Therapeutics
6.13.1 Coave Therapeutics Company Information
6.13.2 Coave Therapeutics Description and Business Overview
6.13.3 Coave Therapeutics AAV-based Gene Therapy Products Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Coave Therapeutics AAV-based Gene Therapy Products Product Portfolio
6.13.5 Coave Therapeutics Recent Developments/Updates
6.14 MeiraGTx
6.14.1 MeiraGTx Company Information
6.14.2 MeiraGTx Description and Business Overview
6.14.3 MeiraGTx AAV-based Gene Therapy Products Sales, Revenue and Gross Margin (2019-2024)
6.14.4 MeiraGTx AAV-based Gene Therapy Products Product Portfolio
6.14.5 MeiraGTx Recent Developments/Updates
6.15 RegenxBio
6.15.1 RegenxBio Company Information
6.15.2 RegenxBio Description and Business Overview
6.15.3 RegenxBio AAV-based Gene Therapy Products Sales, Revenue and Gross Margin (2019-2024)
6.15.4 RegenxBio AAV-based Gene Therapy Products Product Portfolio
6.15.5 RegenxBio Recent Developments/Updates
6.16 Asklepios Biopharmaceutical
6.16.1 Asklepios Biopharmaceutical Company Information
6.16.2 Asklepios Biopharmaceutical Description and Business Overview
6.16.3 Asklepios Biopharmaceutical AAV-based Gene Therapy Products Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Asklepios Biopharmaceutical AAV-based Gene Therapy Products Product Portfolio
6.16.5 Asklepios Biopharmaceutical Recent Developments/Updates
6.17 Audentes Therapeutics
6.17.1 Audentes Therapeutics Company Information
6.17.2 Audentes Therapeutics Description and Business Overview
6.17.3 Audentes Therapeutics AAV-based Gene Therapy Products Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Audentes Therapeutics AAV-based Gene Therapy Products Product Portfolio
6.17.5 Audentes Therapeutics Recent Developments/Updates
6.18 Neurophth
6.18.1 Neurophth Company Information
6.18.2 Neurophth Description and Business Overview
6.18.3 Neurophth AAV-based Gene Therapy Products Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Neurophth AAV-based Gene Therapy Products Product Portfolio
6.18.5 Neurophth Recent Developments/Updates
6.19 Belief BioMed
6.19.1 Belief BioMed Company Information
6.19.2 Belief BioMed Description and Business Overview
6.19.3 Belief BioMed AAV-based Gene Therapy Products Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Belief BioMed AAV-based Gene Therapy Products Product Portfolio
6.19.5 Belief BioMed Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 AAV-based Gene Therapy Products Industry Chain Analysis
7.2 AAV-based Gene Therapy Products Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 AAV-based Gene Therapy Products Production Mode & Process
7.4 AAV-based Gene Therapy Products Sales and Marketing
7.4.1 AAV-based Gene Therapy Products Sales Channels
7.4.2 AAV-based Gene Therapy Products Distributors
7.5 AAV-based Gene Therapy Products Customers
8 AAV-based Gene Therapy Products Market Dynamics
8.1 AAV-based Gene Therapy Products Industry Trends
8.2 AAV-based Gene Therapy Products Market Drivers
8.3 AAV-based Gene Therapy Products Market Challenges
8.4 AAV-based Gene Therapy Products Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global AAV-based Gene Therapy Products Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global AAV-based Gene Therapy Products Market Value by Application (2024-2030) & (US$ Million)
Table 3. Global AAV-based Gene Therapy Products Market Competitive Situation by Manufacturers in 2023
Table 4. Global AAV-based Gene Therapy Products Sales (Units) of Key Manufacturers (2019-2024)
Table 5. Global AAV-based Gene Therapy Products Sales Market Share by Manufacturers (2019-2024)
Table 6. Global AAV-based Gene Therapy Products Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global AAV-based Gene Therapy Products Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market AAV-based Gene Therapy Products Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of AAV-based Gene Therapy Products, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of AAV-based Gene Therapy Products, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of AAV-based Gene Therapy Products, Product Type & Application
Table 12. Global Key Manufacturers of AAV-based Gene Therapy Products, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global AAV-based Gene Therapy Products by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in AAV-based Gene Therapy Products as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global AAV-based Gene Therapy Products Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global AAV-based Gene Therapy Products Sales by Region (2019-2024) & (Units)
Table 18. Global AAV-based Gene Therapy Products Sales Market Share by Region (2019-2024)
Table 19. Global AAV-based Gene Therapy Products Sales by Region (2025-2030) & (Units)
Table 20. Global AAV-based Gene Therapy Products Sales Market Share by Region (2025-2030)
Table 21. Global AAV-based Gene Therapy Products Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global AAV-based Gene Therapy Products Revenue Market Share by Region (2019-2024)
Table 23. Global AAV-based Gene Therapy Products Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global AAV-based Gene Therapy Products Revenue Market Share by Region (2025-2030)
Table 25. North America AAV-based Gene Therapy Products Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America AAV-based Gene Therapy Products Sales by Country (2019-2024) & (Units)
Table 27. North America AAV-based Gene Therapy Products Sales by Country (2025-2030) & (Units)
Table 28. North America AAV-based Gene Therapy Products Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America AAV-based Gene Therapy Products Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe AAV-based Gene Therapy Products Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe AAV-based Gene Therapy Products Sales by Country (2019-2024) & (Units)
Table 32. Europe AAV-based Gene Therapy Products Sales by Country (2025-2030) & (Units)
Table 33. Europe AAV-based Gene Therapy Products Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe AAV-based Gene Therapy Products Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific AAV-based Gene Therapy Products Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific AAV-based Gene Therapy Products Sales by Region (2019-2024) & (Units)
Table 37. Asia Pacific AAV-based Gene Therapy Products Sales by Region (2025-2030) & (Units)
Table 38. Asia Pacific AAV-based Gene Therapy Products Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific AAV-based Gene Therapy Products Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America AAV-based Gene Therapy Products Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America AAV-based Gene Therapy Products Sales by Country (2019-2024) & (Units)
Table 42. Latin America AAV-based Gene Therapy Products Sales by Country (2025-2030) & (Units)
Table 43. Latin America AAV-based Gene Therapy Products Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America AAV-based Gene Therapy Products Revenue Market Share by Country (2019-2024)
Table 45. Middle East and Africa AAV-based Gene Therapy Products Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East and Africa AAV-based Gene Therapy Products Sales by Country (2019-2024) & (Units)
Table 47. Middle East and Africa AAV-based Gene Therapy Products Sales by Country (2025-2030) & (Units)
Table 48. Middle East and Africa AAV-based Gene Therapy Products Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East and Africa AAV-based Gene Therapy Products Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global AAV-based Gene Therapy Products Sales (Units) by Type (2019-2024)
Table 51. Global AAV-based Gene Therapy Products Sales (Units) by Type (2025-2030)
Table 52. Global AAV-based Gene Therapy Products Sales Market Share by Type (2019-2024)
Table 53. Global AAV-based Gene Therapy Products Sales Market Share by Type (2025-2030)
Table 54. Global AAV-based Gene Therapy Products Revenue (US$ Million) by Type (2019-2024)
Table 55. Global AAV-based Gene Therapy Products Revenue (US$ Million) by Type (2025-2030)
Table 56. Global AAV-based Gene Therapy Products Revenue Market Share by Type (2019-2024)
Table 57. Global AAV-based Gene Therapy Products Revenue Market Share by Type (2025-2030)
Table 58. Global AAV-based Gene Therapy Products Price (US$/Unit) by Type (2019-2024)
Table 59. Global AAV-based Gene Therapy Products Price (US$/Unit) by Type (2025-2030)
Table 60. Global AAV-based Gene Therapy Products Sales (Units) by Application (2019-2024)
Table 61. Global AAV-based Gene Therapy Products Sales (Units) by Application (2025-2030)
Table 62. Global AAV-based Gene Therapy Products Sales Market Share by Application (2019-2024)
Table 63. Global AAV-based Gene Therapy Products Sales Market Share by Application (2025-2030)
Table 64. Global AAV-based Gene Therapy Products Revenue (US$ Million) by Application (2019-2024)
Table 65. Global AAV-based Gene Therapy Products Revenue (US$ Million) by Application (2025-2030)
Table 66. Global AAV-based Gene Therapy Products Revenue Market Share by Application (2019-2024)
Table 67. Global AAV-based Gene Therapy Products Revenue Market Share by Application (2025-2030)
Table 68. Global AAV-based Gene Therapy Products Price (US$/Unit) by Application (2019-2024)
Table 69. Global AAV-based Gene Therapy Products Price (US$/Unit) by Application (2025-2030)
Table 70. uniQure Company Information
Table 71. uniQure Description and Business Overview
Table 72. uniQure AAV-based Gene Therapy Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. uniQure AAV-based Gene Therapy Products Product
Table 74. uniQure Recent Developments/Updates
Table 75. Spark Therapeutics Company Information
Table 76. Spark Therapeutics Description and Business Overview
Table 77. Spark Therapeutics AAV-based Gene Therapy Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Spark Therapeutics AAV-based Gene Therapy Products Product
Table 79. Spark Therapeutics Recent Developments/Updates
Table 80. AveXis (Novartis) Company Information
Table 81. AveXis (Novartis) Description and Business Overview
Table 82. AveXis (Novartis) AAV-based Gene Therapy Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. AveXis (Novartis) AAV-based Gene Therapy Products Product
Table 84. AveXis (Novartis) Recent Developments/Updates
Table 85. PTC Therapeutics Company Information
Table 86. PTC Therapeutics Description and Business Overview
Table 87. PTC Therapeutics AAV-based Gene Therapy Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. PTC Therapeutics AAV-based Gene Therapy Products Product
Table 89. PTC Therapeutics Recent Developments/Updates
Table 90. BioMarin Company Information
Table 91. BioMarin Description and Business Overview
Table 92. BioMarin AAV-based Gene Therapy Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. BioMarin AAV-based Gene Therapy Products Product
Table 94. BioMarin Recent Developments/Updates
Table 95. Sarepta Therapeutics Company Information
Table 96. Sarepta Therapeutics Description and Business Overview
Table 97. Sarepta Therapeutics AAV-based Gene Therapy Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Sarepta Therapeutics AAV-based Gene Therapy Products Product
Table 99. Sarepta Therapeutics Recent Developments/Updates
Table 100. Roche Company Information
Table 101. Roche Description and Business Overview
Table 102. Roche AAV-based Gene Therapy Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Roche AAV-based Gene Therapy Products Product
Table 104. Roche Recent Developments/Updates
Table 105. Pfizer Company Information
Table 106. Pfizer Description and Business Overview
Table 107. Pfizer AAV-based Gene Therapy Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Pfizer AAV-based Gene Therapy Products Product
Table 109. Pfizer Recent Developments/Updates
Table 110. CSL Behring Company Information
Table 111. CSL Behring Description and Business Overview
Table 112. CSL Behring AAV-based Gene Therapy Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. CSL Behring AAV-based Gene Therapy Products Product
Table 114. CSL Behring Recent Developments/Updates
Table 115. Sangamo Therapeutics Company Information
Table 116. Sangamo Therapeutics Description and Business Overview
Table 117. Sangamo Therapeutics AAV-based Gene Therapy Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Sangamo Therapeutics AAV-based Gene Therapy Products Product
Table 119. Sangamo Therapeutics Recent Developments/Updates
Table 120. Biogen Company Information
Table 121. Biogen Description and Business Overview
Table 122. Biogen AAV-based Gene Therapy Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Biogen AAV-based Gene Therapy Products Product
Table 124. Biogen Recent Developments/Updates
Table 125. Freeline Therapeutics Company Information
Table 126. Freeline Therapeutics Description and Business Overview
Table 127. Freeline Therapeutics AAV-based Gene Therapy Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Freeline Therapeutics AAV-based Gene Therapy Products Product
Table 129. Freeline Therapeutics Recent Developments/Updates
Table 130. Coave Therapeutics Company Information
Table 131. Coave Therapeutics Description and Business Overview
Table 132. Coave Therapeutics AAV-based Gene Therapy Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. Coave Therapeutics AAV-based Gene Therapy Products Product
Table 134. Coave Therapeutics Recent Developments/Updates
Table 135. MeiraGTx Company Information
Table 136. MeiraGTx Description and Business Overview
Table 137. MeiraGTx AAV-based Gene Therapy Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138. MeiraGTx AAV-based Gene Therapy Products Product
Table 139. MeiraGTx Recent Developments/Updates
Table 140. RegenxBio Company Information
Table 141. RegenxBio Description and Business Overview
Table 142. RegenxBio AAV-based Gene Therapy Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 143. RegenxBio AAV-based Gene Therapy Products Product
Table 144. RegenxBio Recent Developments/Updates
Table 145. Asklepios Biopharmaceutical Company Information
Table 146. Asklepios Biopharmaceutical Description and Business Overview
Table 147. Asklepios Biopharmaceutical AAV-based Gene Therapy Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 148. Asklepios Biopharmaceutical AAV-based Gene Therapy Products Product
Table 149. Asklepios Biopharmaceutical Recent Developments/Updates
Table 150. Audentes Therapeutics Company Information
Table 151. Audentes Therapeutics Description and Business Overview
Table 152. Audentes Therapeutics AAV-based Gene Therapy Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 153. Audentes Therapeutics AAV-based Gene Therapy Products Product
Table 154. Audentes Therapeutics Recent Developments/Updates
Table 155. Neurophth Company Information
Table 156. Neurophth Description and Business Overview
Table 157. Neurophth AAV-based Gene Therapy Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 158. Neurophth AAV-based Gene Therapy Products Product
Table 159. Neurophth Recent Developments/Updates
Table 160. Belief BioMed Company Information
Table 161. Belief BioMed Description and Business Overview
Table 162. Belief BioMed AAV-based Gene Therapy Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 163. Belief BioMed AAV-based Gene Therapy Products Product
Table 164. Belief BioMed Recent Developments/Updates
Table 165. Key Raw Materials Lists
Table 166. Raw Materials Key Suppliers Lists
Table 167. AAV-based Gene Therapy Products Distributors List
Table 168. AAV-based Gene Therapy Products Customers List
Table 169. AAV-based Gene Therapy Products Market Trends
Table 170. AAV-based Gene Therapy Products Market Drivers
Table 171. AAV-based Gene Therapy Products Market Challenges
Table 172. AAV-based Gene Therapy Products Market Restraints
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
Table 176. Authors List of This Report
List of Figures
Figure 1. Product Picture of AAV-based Gene Therapy Products
Figure 2. Global AAV-based Gene Therapy Products Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global AAV-based Gene Therapy Products Market Share by Type: 2023 & 2030
Figure 4. AAV2 Product Picture
Figure 5. AAV8 Product Picture
Figure 6. AAV9 Product Picture
Figure 7. Others Product Picture
Figure 8. Global AAV-based Gene Therapy Products Market Value by Application (2024-2030) & (US$ Million)
Figure 9. Global AAV-based Gene Therapy Products Market Share by Application: 2023 & 2030
Figure 10. Haematology
Figure 11. Ophthalmology
Figure 12. Neurology
Figure 13. Musculoskeletal
Figure 14. Others
Figure 15. Global AAV-based Gene Therapy Products Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global AAV-based Gene Therapy Products Market Size (2019-2030) & (US$ Million)
Figure 17. Global AAV-based Gene Therapy Products Sales (2019-2030) & (Units)
Figure 18. Global AAV-based Gene Therapy Products Average Price (US$/Unit) & (2019-2030)
Figure 19. AAV-based Gene Therapy Products Report Years Considered
Figure 20. AAV-based Gene Therapy Products Sales Share by Manufacturers in 2023
Figure 21. Global AAV-based Gene Therapy Products Revenue Share by Manufacturers in 2023
Figure 22. Global 5 and 10 Largest AAV-based Gene Therapy Products Players: Market Share by Revenue in AAV-based Gene Therapy Products in 2023
Figure 23. AAV-based Gene Therapy Products Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 24. Global AAV-based Gene Therapy Products Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 25. North America AAV-based Gene Therapy Products Sales Market Share by Country (2019-2030)
Figure 26. North America AAV-based Gene Therapy Products Revenue Market Share by Country (2019-2030)
Figure 27. United States AAV-based Gene Therapy Products Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. Canada AAV-based Gene Therapy Products Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Europe AAV-based Gene Therapy Products Sales Market Share by Country (2019-2030)
Figure 30. Europe AAV-based Gene Therapy Products Revenue Market Share by Country (2019-2030)
Figure 31. Germany AAV-based Gene Therapy Products Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. France AAV-based Gene Therapy Products Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. U.K. AAV-based Gene Therapy Products Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Italy AAV-based Gene Therapy Products Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Russia AAV-based Gene Therapy Products Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Asia Pacific AAV-based Gene Therapy Products Sales Market Share by Region (2019-2030)
Figure 37. Asia Pacific AAV-based Gene Therapy Products Revenue Market Share by Region (2019-2030)
Figure 38. China AAV-based Gene Therapy Products Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Japan AAV-based Gene Therapy Products Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. South Korea AAV-based Gene Therapy Products Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. India AAV-based Gene Therapy Products Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Australia AAV-based Gene Therapy Products Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. China Taiwan AAV-based Gene Therapy Products Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Southeast Asia AAV-based Gene Therapy Products Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Latin America AAV-based Gene Therapy Products Sales Market Share by Country (2019-2030)
Figure 46. Mexico AAV-based Gene Therapy Products Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Brazil AAV-based Gene Therapy Products Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Argentina AAV-based Gene Therapy Products Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Colombia AAV-based Gene Therapy Products Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Middle East and Africa AAV-based Gene Therapy Products Sales Market Share by Country (2019-2030)
Figure 51. Middle East and Africa AAV-based Gene Therapy Products Revenue Market Share by Country (2019-2030)
Figure 52. Turkey AAV-based Gene Therapy Products Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia AAV-based Gene Therapy Products Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. UAE AAV-based Gene Therapy Products Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. Global Sales Market Share of AAV-based Gene Therapy Products by Type (2019-2030)
Figure 56. Global Revenue Market Share of AAV-based Gene Therapy Products by Type (2019-2030)
Figure 57. Global AAV-based Gene Therapy Products Price (US$/Unit) by Type (2019-2030)
Figure 58. Global Sales Market Share of AAV-based Gene Therapy Products by Application (2019-2030)
Figure 59. Global Revenue Market Share of AAV-based Gene Therapy Products by Application (2019-2030)
Figure 60. Global AAV-based Gene Therapy Products Price (US$/Unit) by Application (2019-2030)
Figure 61. AAV-based Gene Therapy Products Value Chain
Figure 62. AAV-based Gene Therapy Products Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
